Clinical Trials Browser

Completed × Interventional × Acromegaly × Clear all

NCT01794793 2024-10-01

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Acromegaly, Dumping Syndrome, Melanoma, Neoplasms, Pituitary Neoplasms, Prostatic Neoplasms, Neuroendocrine Tumors, Pituitary ACTH Hypersecretion

NCT01673646 2019-09-16

Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism

Phase 2 Completed

33 enrolled 24 charts

Endocrine

Acromegaly, Gigantism, Growth Disorders, Pituitary Neoplasms

NCT02299089 2017-12-15

Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)

Phase 2 Completed

12 enrolled 18 charts

EndocrineNET

Acromegaly, Neuroendocrine Tumors, Serotonin Syndrome

NCT00376064 2017-03-06

Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly

Phase 4 Completed

20 enrolled

CNSEndocrine

Acromegaly, Brain Neoplasms, Pituitary Neoplasms

NCT00171886 2017-02-24

Octreotide Efficacy and Safety in First-line Acromegalic Patients

Phase 4 Completed

20 enrolled

Acromegaly

NCT00001860 2008-03-04

Sandostatin LAR Depot vs. Surgery for Treating Acromegaly

Phase 2 Completed

5 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms

NCT00017927 2008-03-04

A Study of the Effects of Pegvisomant on Growth Hormone Excess in McCune-Albright Syndrome

Phase 3 Completed

10 enrolled

Acromegaly, Adenoma, Fibrous Dysplasia, Polyostotic, Hyperplasia

NCT00627796 2008-03-03

ATG1line

Phase 4 Completed

27 enrolled

Acromegaly, Neoplasms

NCT00461149 2007-04-17

HDacro

Phase 4 Completed

50 enrolled

Endocrine

Acromegaly, Pituitary Neoplasms